CA-PICSART
6.4.2021 14:02:11 CEST | Business Wire | Press release
PicsArt , the world’s largest creative platform, today announced the opening of its newest office in the U.K. Headquartered in San Francisco, PicsArt’s workforce spans the globe with growing offices and employees in Yerevan, Armenia, Los Angeles, Moscow, Beijing, Tokyo and India. In the past year alone, PicsArt has expanded its employee headcount by 36%. Establishing a new office in the U.K. is PicsArt’s latest move in its strategy to meet the needs of its user base of more than 150 million monthly active creators worldwide.
The announcement follows PicsArt’s recent hiring of its VP of Design, acclaimed designer Duncan Riley, who is based in the U.K. In this role, Riley will lead the expansion of the new hub, which will be focused on Product Development and Design. Riley brings more than 18 years of experience growing creative teams and crafting global user experiences for a host of leading brands, including Shazam, Skyscanner, Snapchat, NBCUniversal, Viacom, Absolute Radio and more.
“At PicsArt we are building the best all-round creator experience possible, allowing anyone and everyone to perfect their everyday moments, express their passions, promote their business, or even create art. I'm excited to get started with the incredible talent here at PicsArt, and begin growing the UK-based team to support our vision in 2021,” Riley shared.
Of the buildout, PicsArt founder and CEO Hovhannes Avoyan says, “As a globally-minded and operated company of more than 700 employees, our goal is to best serve the many ways PicsArt creators use our product across the world. We are excited to come to the U.K. and welcome new members and all of their insights and contributions to build amazing things together for our active and dynamic user base.”
In addition to hiring for its new U.K. hub, PicsArt is actively hiring in other global regions - including remote-based positions - in design, engineering, product operations, marketing, content, and more. For more information on current open roles, prospective applicants can visit https://picsart.com/jobs .
About PicsArt
PicsArt is the world’s #1 creative platform and a top 20 most downloaded app for seven consecutive quarters. Every month, the PicsArt community creates, remixes and shares billions of visual stories using the company’s powerful and easy-to-use editing tools. PicsArt has amassed one of the largest open-source content collections in the world, including free-to-edit photos, stickers, backgrounds, templates and more. PicsArt is available in 30 languages for free and as a subscription on iOS, Android and Windows devices. PicsArt is backed by Sequoia Capital, DCM Ventures, Insight Partners, and Siguler Guff & Company. Download the app or visit picsart.com or picsart.com/brands/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom